Kimberly Westrich, M.A., chief strategy officer of National Pharmaceutical Council, shares her prediction for 2025.

In a review of previous studies, researchers found that the images seen on social media contribute to taking actions that are ...

The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...

Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD ...

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions ...

Health plans will need to navigate a difficult financial environment caused by increased healthcare costs and potential ...

The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...

Fianlimab plus Libtayo demonstrated persistent and significant clinical activity in patients with advanced melanoma.

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

A small study of 18 patients with skin cancer found that the combination of vitamin D and chemotherapy provided an immune ...

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...